Meridian Bioscience (Nasdaq: VIVO) reported earnings on Nov. 8. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q4), Meridian Bioscience beat slightly on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share increased significantly.

Margins grew across the board.

Revenue details
 Meridian Bioscience recorded revenue of $43.7 million. The eight analysts polled by S&P Capital IQ expected net sales of $43.2 million on the same basis. GAAP reported sales were 5.7% higher than the prior-year quarter's $41.3 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.21. The nine earnings estimates compiled by S&P Capital IQ predicted $0.19 per share. GAAP EPS of $0.21 for Q4 were 31% higher than the prior-year quarter's $0.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 63.5%, 550 basis points better than the prior-year quarter. Operating margin was 27.6%, 250 basis points better than the prior-year quarter. Net margin was 19.6%, 340 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $44.4 million. On the bottom line, the average EPS estimate is $0.19.

Next year's average estimate for revenue is $188.0 million. The average EPS estimate is $0.88.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 467 members out of 479 rating the stock outperform, and 12 members rating it underperform. Among 112 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 109 give Meridian Bioscience a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is outperform, with an average price target of $17.00.

Can your retirement portfolio provide you with enough income to last? You'll need more than Meridian Bioscience. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.